Safrazine
 | |
| Systematic (IUPAC) name | |
|---|---|
|
[3-(1,3-benzodioxol-5-yl)-1-methyl-propyl]hydrazine | |
| Clinical data | |
| Legal status |
|
| Routes of administration | Oral |
| Identifiers | |
| CAS Number | 33419-68-0 |
| ATC code | None |
| PubChem | CID 34042 |
| ChemSpider | 31375 |
| UNII | F5G0P5378C |
| Synonyms | 4-benzo[1,3]dioxol-5-ylbutan-2-ylhydrazine; [3-(3,4-(methylenedioxy)phenyl)-1-butyl]hydrazine; 2-piperonylisopropylhydrazine |
| Chemical data | |
| Formula | C11H16N2O2 |
| Molar mass | 208.26 g/mol |
Safrazine (Safra) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was introduced as an antidepressant in the 1960s, but has since been discontinued.[1]
See also
References
- ↑ Dr. Ian Morton; I.K. Morton; Judith M. Hall (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 251–. ISBN 978-0-7514-0499-9.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||
This article is issued from Wikipedia - version of the Friday, January 08, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.